mo:re, a German life science startup, has raised 鈧�2.3m in seed funding to accelerate the commercialisation of its lab platform for complex cell culture workflows. High-Tech Gr眉nderfonds (HTGF) led the round, with participation from Innovationsstarter Fonds Hamburg (IFH), Gilson, NEDGEX, Nidobirds Ventures, and private investors R&R Medical and Martin Bl眉ggel.
There is much agreement in the scientific community that organoids represent a significant step in the evolution to more representative disease modelling. The path to faster approval of more relevant drugs includes modern organoid models. This has been recognised by the US Food and Drug Administration (FDA) as well, with their new guidelines clearing the path to replacing animal experiments with relevant organoid models. The field is missing the means for broad application of organoids in higher throughput that achieves reproducible results in a standardised environment.
mo:re has developed a groundbreaking lab platform, combining automation and software for planning, executing, and analysis of cell culture studies. The user-friendly platform aims to simplify cell culture, making organoids accessible as a standard lab technique and providing verifiable results. The lab automation device covers all relevant process steps, setting a new benchmark for scalability, reproducibility, and standardisation of 3D cell culture models.
鈥淲ith this funding, we want to establish our presence in the market and continue building our team. Now it is time to focus our resources on developing further scientific applications to unlock the potential our platform has to offer together with our customers, as well as our internal R&D lab.鈥� 鈥� Lukas Gaats, CEO at mo:re
鈥淭he team of mo:re is poised to execute on its vision to provide easy access to a standardised way of performing 3D cell culture and obtain reproducible results for researchers worldwide.鈥� 鈥� Dr Christian Kannemeier, Senior Investment Manager at HTGF
鈥淥ur investment in mo:re reflects our confidence in their visionary product to tackle cell culture challenges. Their platform can redefine the landscape of non-animal methods in the life science industry.鈥� 鈥� Stefanie H枚hn, Senior Investment Manager at IFH
鈥淰erifiable data in drug discovery and development are crucial for accelerating creation of new and effective pharmaceuticals. mo:re鈥檚 innovative technological approach provides an important step toward standardising organoid growth, significantly enhancing their quality. This will not only improve the speed and reliability of drug discovery but also deliver more consistent results for research, ultimately reducing the reliance on animal testing.鈥� 鈥� Dirk Freystadt, SVP of Corporate Development at Gilson